AUPH · Aurinia Pharmaceuticals Inc. · Earnings Calls, Transcripts & Webcasts
$14.70
-0.19 (-1.28%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$1.97B
Shares
134.00M
Volume · Nov 20
1.34M
Avg daily vol (3M)
864.89K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Aurinia Pharmaceuticals Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Aurinia Pharmaceuticals Inc. (AUPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY25 · Q4
2026-02-26
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Confident tone
Diagnostic and treatment paradigm strategy
Combination therapy research
Competitive landscape and market growth
Revenue
$77.11M
▲ 28.8% YoY Diluted EPS
$1.53
▲ 15200% YoY Gross margin
88.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Confident tone
Aritinercept development
Raised 2025 financial guidance
LUPKYNIS commercial growth
Revenue
$73.47M
▲ 8.4% YoY Diluted EPS
$0.23
▲ 130% YoY Gross margin
88.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Confident tone
Revenue and earnings momentum
LUPKYNIS commercial growth
Aritinercept (AUR200) pipeline
Revenue
$70.01M
▲ 22.4% YoY Diluted EPS
$0.16
▲ 1500% YoY Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-06-30
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript
Confident tone
LUPKYNIS commercial growth
AUR200 pipeline (Phase 1 SAD)
ACR/EULAR/KDIGO guidelines and first-line positioning
Revenue
$62.47M
▲ 24.2% YoY Diluted EPS
$0.16
Gross margin
86.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call
Confident tone
AUR200 pipeline development
2025 financial guidance
LUPKYNIS revenue growth
Revenue
$59.87M
▲ 32.8% YoY Diluted EPS
$0.01
Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2024 Earnings Call Transcript
Positive tone
LUPKYNIS commercial performance
Japan regulatory approval and Otsuka partnership
ENLIGHT-LN registry and real-world evidence
Revenue
$67.77M
▲ 24.3% YoY Diluted EPS
$0.10
Gross margin
91.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2024 Earnings Call Transcript
Confident tone
Revenue and commercial growth
AUR200 pipeline development
Otsuka partnership and international expansion
Revenue
$57.19M
▲ 37.8% YoY Diluted EPS
$0.01
Gross margin
84.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript
Confident tone
Lupus nephritis market opportunity and awareness
LUPKYNIS commercial performance
Corporate restructuring and cost reduction
Revenue
$50.30M
▲ 46.2% YoY Diluted EPS
$-0.07
Gross margin
84.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript
Positive tone
Patient growth metrics
LUPKYNIS commercial performance
Physician and patient education
Revenue
$45.09M
▲ 58.6% YoY Diluted EPS
$-0.19
Gross margin
88.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript
Revenue
$54.52M
▼ 2.3% YoY Diluted EPS
$-0.09
Gross margin
87.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call Transcript
Revenue
$41.49M
▲ 47.2% YoY Diluted EPS
$-0.08
Gross margin
96.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Call Transcript
Revenue
$34.41M
▲ 59.1% YoY Diluted EPS
$-0.18
Gross margin
98.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Call Transcript
Revenue
$28.43M
▲ 21.5% YoY Diluted EPS
$-0.18
Gross margin
95.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Call Transcript
Revenue
$55.78M
▲ 280.3% YoY Diluted EPS
$-0.06
Gross margin
95.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2022 Earnings Call Transcript
Revenue
$28.19M
▲ 325.8% YoY Diluted EPS
$-0.25
Gross margin
94.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2022 Earnings Call Transcript
Revenue
$21.62M
▲ 2266% YoY Diluted EPS
$-0.27
Gross margin
98.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2021 Earnings Call Transcript
Revenue
$23.40M
▼ 53.2% YoY Diluted EPS
$-0.25
Gross margin
97.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2021 Earnings Call Transcript
Revenue
$14.67M
▲ 50475.9% YoY Diluted EPS
$-0.39
Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2021 Earnings Call Transcript
Revenue
$6.62M
▲ 22727.6% YoY Diluted EPS
$-0.37
Gross margin
95.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2021 Earnings Call Transcript
Revenue
$914,000
▲ 2946.7% YoY Diluted EPS
$-0.40
Gross margin
94.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2020 Earnings Call Transcript
Revenue
$50.03M
▲ 172417.2% YoY Diluted EPS
$-0.06
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2020 Earnings Call Transcript
Revenue
$29,000
▼ 87.4% YoY Diluted EPS
$-0.34
Gross margin
100.0%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Earnings Call Transcript
Revenue
$29,000
▲ 0% YoY Diluted EPS
$-0.24
Gross margin
100.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2020 Earnings Call Transcript
Revenue
$30,000
▲ 0% YoY Diluted EPS
$-0.23
Gross margin
100.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 webcasts
Key facts
CIK
1600620
CUSIP
05156V102
13F (30d)
285 filings
254 filers
Visit website
Investor relations